stars 1 stars 2 stars 3

Endoluminal Sciences is a Sydney, Australia-based, venture capital-backed company committed to the development of novel, platform technologies to dramatically enhance the clinical performance of endovascular prostheses. While its novel technologies are foreseen to have applications in a range of vascular disease states, the immediate focus is the transcatheter treatment of structural heart disease. The company is financed by GBS Venture Partners, Australia's leading healthcare venture capital firm, and Reidsdale Investments.

Endoluminal Sciences Pty Ltd Questions

The Endoluminal Sciences Pty Ltd annual revenue was $5 million in 2026.

Martin Ng is the Founder and Chief Medical Officer of Endoluminal Sciences Pty Ltd.

2 people are employed at Endoluminal Sciences Pty Ltd.

Endoluminal Sciences Pty Ltd is based in Sydney, New South Wales.

The NAICS codes for Endoluminal Sciences Pty Ltd are [33, 339].

The SIC codes for Endoluminal Sciences Pty Ltd are [384, 38].

Top Endoluminal Sciences Pty Ltd Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users